Pill for advanced pancreatic cancer shows promise
In a phase one/two trial, researchers combined the once-a-day pill daraxonrasib with chemotherapy for people with advanced pancreatic cancer. Tumours shrank or disappeared in 60.7% of patients, and the disease stopped growing in 90.2% of the 61 people studied. These results are notable because advanced pancreatic cancer is difficult to treat. The combination produced a complete response, meaning tumours were no longer detectable, in 8.2% of patients. The trial team also reported that tumours took an average of 12.8 months to return or start growing again across the group. Daraxonrasib targets mutated KRAS, a gene found in more than nine in 10 pancreatic tumours that signals cancer cells to grow. The findings are encouraging but come from a small, early-stage study, with typical follow-up of 18 months. One-year survival was 76.6%, compared with around 40% to 45% with chemotherapy alone. A larger phase-three trial is needed before the treatment can be assessed for NHS use, and longer-term survival data are still to come.
What happened when daraxonrasib was combined with chemotherapy in the trial?
In a phase one/two trial, researchers combined the once-a-day pill daraxonrasib with chemotherapy for people with advanced pancreatic cancer. Tumours shrank or disappeared in 60.7% of patients, and the disease stopped growing in 90.2% of the 61 people studied. These results are notable because advanced pancreatic cancer is difficult to treat.
The combination produced a complete response, meaning tumours were no longer detectable, in 8.2% of patients. The trial team also reported that tumours took an average of 12.8 months to return or start growing again across the group. Daraxonrasib targets mutated KRAS, a gene found in more than nine in 10 pancreatic tumours that signals cancer cells to grow.
The findings are encouraging but come from a small, early-stage study, with typical follow-up of 18 months. One-year survival was 76.6%, compared with around 40% to 45% with chemotherapy alone. A larger phase-three trial is needed before the treatment can be assessed for NHS use, and longer-term survival data are still to come.
How many patients saw their tumours shrink or disappear, and how many had no detectable tumour?
The phase one/two study included 61 patients receiving daraxonrasib with chemotherapy. Tumours shrank or disappeared in 60.7% of them. That figure includes both partial reductions and complete responses, so it does not mean that all those patients’ tumours vanished. The results were reported at a typical follow-up of 18 months.
A complete response, reported in 8.2% of patients, means their tumours were no longer detectable. Dr Wungki Park described this as about one in 12 people. The researchers also reported a disease control rate of 90.2%: in that share of the group, tumours stopped growing over a typical period of 18 months. These are separate measures of how the cancer responded.
The figures are promising, but they come from a small, early-stage trial and do not establish how long complete responses will last. Dr Park said longer-term survival data would come as the trial progressed. A larger phase-three study is under way in the US, with some European sites potentially having space. More research is needed before the treatment can be assessed for NHS use.
What does a “complete response” mean, and does having no detectable tumour on a scan prove someone is cured?
In this trial, a complete response meant that a patient’s tumour was no longer detectable. The researchers reported complete responses in 8.2% of participants, or about one in 12, after a typical follow-up of 18 months. This is different from saying that a tumour merely shrank or stopped growing, and it is an important measure of how treatment affected the disease.
A scan that shows no detectable tumour does not, by itself, prove that a person is cured. The study report describes what could be seen on scans; it does not establish that cancer can never return. Dr Wungki Park called these results the closest to a cure and said the complete responses were unprecedented in metastatic pancreatic cancer.
The findings remain early: this was a phase one/two trial involving 61 patients. Dr Park said longer-term survival data would come as the trial progressed, and noted that cancer can develop resistance to treatment. A larger phase-three study is needed before the drug can be assessed for NHS use. So the results offer hope, but they are not evidence of a confirmed cure.
How did the proportion of patients alive after one year compare with chemotherapy alone?
One year after treatment, 76.6% of patients in the daraxonrasib-and-chemotherapy trial were still alive. The article compares this with around 40% to 45% of patients receiving chemotherapy alone. That difference is a striking early survival signal in a cancer described as aggressive and difficult to treat.
The combination was tested in a phase one/two clinical trial involving 61 patients. Alongside the survival figure, tumours shrank or disappeared in 60.7% of participants, while tumours stopped growing in 90.2%. Daraxonrasib works by locking onto mutated KRAS, which is found in more than nine in 10 pancreatic tumours and continuously signals cancer cells to grow.
The survival comparison is encouraging, but the study is small and early, and the article does not provide a detailed account of how the chemotherapy comparison was made. Dr Wungki Park said longer-term survival data would come as the trial progressed. A larger phase-three trial is needed before the treatment can be assessed for use on the NHS. The results do not yet establish its long-term benefit.
What is KRAS, and how does daraxonrasib target the mutation that helps pancreatic cancer cells grow?
KRAS is a gene, and the article focuses on a mutated form found in more than nine in 10 pancreatic tumours. In these tumours, mutated KRAS continuously signals cancer cells to grow. That makes it a significant target for a treatment designed to interfere with the signal.
Daraxonrasib is a once-a-day pill that locks onto mutated KRAS. By shutting off the signal, the drug can prevent tumours from spreading, according to the article. Researchers tested it alongside chemotherapy in a phase one/two trial. Tumours shrank or disappeared in 60.7% of the 61 patients, while tumours stopped growing in 90.2% over a typical period of 18 months.
These findings suggest the combination may have an effect, but the trial was small and early. One-year survival was 76.6%, compared with around 40% to 45% for chemotherapy alone, and complete responses occurred in 8.2%. The researchers say longer-term survival information will come as the trial progresses. A larger phase-three study is needed before the treatment can be assessed for NHS use.
Why do promising phase one/two results need to be tested in a larger phase-three trial before a treatment can be widely used?
The daraxonrasib-and-chemotherapy findings come from a phase one/two trial of 61 patients. The results are encouraging, but a small early study cannot settle how reliably a treatment works across a larger group or how its benefits and harms compare. The article describes the findings as initial and says more trials are needed before the treatment can be assessed for the NHS.
In standard clinical research, a phase-three trial tests a treatment in a larger group to confirm earlier results and build a stronger picture of its safety and effectiveness. Depending on its design, it may also compare treatment outcomes with standard care. These are general features of clinical trials; the article does not give details of the phase-three trial’s design.
The article says the final phase-three study in the US has enough patients, though some European sites may have space. This next stage matters because a treatment needs stronger evidence before it can be considered for broad use. Cancer Research UK’s chief executive also said more trials are needed before the drug can be assessed for NHS use, and longer-term survival data are still to come.
What does the pancreas do, and why can cancer that starts there be so difficult to treat?
The article does not explain the pancreas’s normal role. As general medical knowledge, the pancreas helps the body digest food by making digestive enzymes, and it makes hormones such as insulin that help regulate blood sugar. Cancer begins when cells in the organ grow abnormally. These basic functions are not discussed in the supplied article.
The article does describe pancreatic cancer as one of the deadliest and most difficult-to-treat cancers. It reports that half of people with the disease die within three months of diagnosis, and that more than 10,000 people in the UK die from it each year. It also focuses on advanced, aggressive disease and a trial using daraxonrasib with chemotherapy.
The article does not explain in detail why pancreatic cancer is so difficult to treat. In general medical knowledge, it is often found at an advanced stage, when treatment is more challenging. The article’s figures underline the urgency: more than 11,000 people are diagnosed in the UK each year. Researchers hope new treatments can improve outcomes, but larger trials are needed before this drug can be assessed for NHS use.
This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.
Read more in the JupiteX app
Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.
Or read more news on the web